News | Stents | February 24, 2020

Biotronik's Orsiro Stent Continues Excellent Results After Three Years

Data from BIOFLOW-V Trial reinforces Orsiro's ability to outperform Abbott's Xience

Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the 2020 Cardiovascular Research Technologies (CRT) Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro coronary drug-eluting stent (DES), which is the first DES to outperform Xience.

February 24, 2020 — Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the 2020 Cardiovascular Research Technologies (CRT) Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro coronary drug-eluting stent (DES), which is the first DES to outperform Xience.[1,2] The new study results have been simultaneously published in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.[3]

Orsiro received FDA approval in 2019 and has been used to treat more than 2 million patients worldwide to date. 

Orsiro's clinical performance in the pivotal BIOFLOW-V trial demonstrated significantly lower rates for target lesion failure (TLF) and target vessel myocardial infarction (MI) at 12 months in comparison to Xience in a large, complex patient population (n=1,334).2 At two years, treatment with Orsiro further improved event rates in comparison to Xience, including a significant reduction in target lesion revascularization (TLR) and spontaneous MI.[3]

 

Three-year Clinical Trial Results for the Orsiro Coronary Stent

The three-year results show Orsiro's ability to outperform Xience, long considered the benchmark for clinical performance, across the most important three-year secondary endpoints of BIOFLOW-V4:
   • 40% lower TLF rate in favor of Orsiro (8.6% versus 14.4% TLF rate, p=0.003)
   •  52% lower ischemia-driven TLR rate (3.4% versus 6.9%, p=0.008)
   •  46% lower rate of TV-MI (5.5% versus 10.1%, p=0.004)
   • 90% lower late/very late definite/probable stent thrombosis (ST) rate (0.1% vs. 1.2%, p=0.018)

"Orsiro sets a new standard for safety and efficacy in long-term clinical endpoints, including statistically lower target lesion revascularization and target vessel MI rates," said David Kandzari, M.D., BIOFLOW-V U.S. principal investigator, Piedmont Heart Institute, Atlanta. "BIOFLOW-V data are the best clinical outcomes observed among comparative clinical trials with contemporary DES. It was widely believed that safety and efficacy with DES had plateaued, but Orsiro has surpassed the limits. Year after year the results have been impressive."

The Orsiro cobalt chromium metal stent elutes sirolimus via BIOlute, Biotronik's  bio-absorbable polymer coating. Beneath the bioabsorbable layer is the company's proBIO coating, a silicon carbide layer covering the bare metal surface and designed to reduce nickel ion release. The Orsiro stent system provides ultrathin stent struts without compromising radial strength and a low crossing profile for easier lesion cross in complex PCI.
 
Orsiro is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4 mm and a lesion length of ≤ 36 mm.

For more information: www.biotronik.com

 

References:

1. Kandzari D et al. The Lancet. 2017, 390(10105).

2. Kandzari D et al. Journal of the American College of Cardiology. 2018, 72(25).

3. Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j.jcin.2020.02.019. 

 

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo